Promoter DNA methylation of Oncostatin M receptor-β as a novel diagnostic and therapeutic marker in colon cancer

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Kim, Myoung Sook ^a   Louwagie, Joost ^b   Carvalho, Beatriz ^c   Terhaar sive Droste, Jochim S ^c   Park, Hannah Lui ^a   Chae, Young Kwang ^d   Yamashita, Keishi ^a   Liu, Junwei ^a   Ostrow, Kimberly Laskie ^a   Ling, Shizhang ^a   Guerrero Preston, Rafael ^a   Demokan, Semra ^a   Yalniz, Zubeyde ^e   Dalay, Nejat ^e   Meijer, Gerrit A ^c   Van Criekinge, Wim ^b   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OncoMethylome Sciences SA   (Belgium)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d ALBERT EINSTEIN MEDICAL CENTER   (United States)

^e ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; APC PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIN A1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; DNA; GAMMA TUBULIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYOD1 PROTEIN; ONCOSTATIN M RECEPTOR BETA; PROTEIN MLH1; RETINOIC ACID RECEPTOR BETA; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSCRIPTION FACTOR CDX1; WT1 PROTEIN; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DNA METHYLATION; DRUG TARGETING; EPIGENETICS; FECES ANALYSIS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; COLORECTAL TUMOR; GENETIC EPIGENESIS; GENETICS; IMMUNOHISTOCHEMISTRY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; ONCOSTATIN M RECEPTOR BETA SUBUNIT; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 68449085638     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006555     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10-30.
2. Arnold CN, Goel A, Blum HE, Boland CR (2005) Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 104: 2035-2047.
3. Fearon ER, Vogelstein B (1999) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
4. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159-170.
5. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
6. Herman JG (1999) Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 9: 359-367.
7. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116.
8. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128: 683-692.
9. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, et al. (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63: 1114-1121.
10. Xu XL, Yu J, Zhang HY, Sun MH, Gu J, et al. (2004) Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 10: 3441-3454.
11. Lind GE, Thorstensen L, Lovig T, Meling GI, Hamelin R, et al. (2004) A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer 3: 28.
12. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, et al. (2008) Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 68: 2661-2670.
13. Kim MV, Chang X, Nagpal JK, Yamashita K, Baek JH, et al. (2008) The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Oncogene 27: 2045-2054.
14. Kim MS, Yamashita K, Baek JH, Park HL, Carvalho AL, et al. (2006) N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 66: 3409-3418.
15. Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, et al. (2007) Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene 26: 881-892.
16. Uthoff SM, Eichenberger MR, McAuliffe TL, Hamilton CJ, Galandiuk S (2001) Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer. Mol Carcinog 1: 56-62.
17. Qi J, Zhu YQ, Luo J, Tao WH (2006) Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol 12: 7113-7117.
18. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, et al. (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36: 417-422.
19. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, et al. (1986) Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A 83: 9739-9743.
20. Grant SL, Begley CG (1999) The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today 5: 406-412.
21. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, et al. (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10: 3001-3007.
22. Xu XL, Yu J, Zhang HY, Sun MH, Gu J, et al. (2004) Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 10: 3441-3454.
23. Lind GE, Thorstensen L, Løvig T, Meling GI, Hamelin R, et al. (2004) A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer 3: 28.
24. Deng G, Kakar S, Okudiara K, Choi E, Sleisenger MH, et al. (2009) Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs. Clin Cancer Res 15: 1519-1526.
25. Zhu X, Chen S, Yin X, Shen A, Ji S, et al. (2003) Constitutively active PKB/Akt inhibited apoptosis and down-regulated beta1,4-galactosyltransferase 1 in hepatocarcinoma cells. Biochem Biophys Res Commun 309: 279-285.
26. Seko A, Hara-Kuge S, Yonezawa S, Nagata K, Yamashita K (1998) Identification and characterization of N-acetylglucosamine-6-O-sulfate-specific beta1,4-galactosyltransferase in human colorectal mucosa. FEBS Lett 440: 307-310.
27. Alahari SK, Nasrallah H (2004) A membrane proximal region of the integrin 5 subunit is important for its interaction with nischarin. Biochem J 377: 449-457.
28. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, et al. (2002) Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 29: 175-192.
29. Zhu X, Jiang J, Shen H, Wang H, Zong H, et al. (2005) Elevated beta1,4-galactosyltransferase I in highly metastatic human lung cancer cells. Identification of E1AF as important transcription activator. J Biol Chem 280: 12503-12516.
30. Li Z, Zong H, Kong X, Zhang S, Wang H, et al. (2006) Cell surface beta 1, 4-galactosyltransferase 1 promotes apoptosis by inhibiting epidermal growth factor receptor pathway. Mol Cell Biochem 291: 69-76.
31. Zhang S, Cai M, Zhang SW, Hu Y, Gu JX (2003) Involvement of beta 1,4 galactosyltransferase 1 and Gal beta1 - >4GlcNAc groups in human hepatocarcinoma cell apoptosis. Mol Cell Biochem 243: 81-86.
32. Asano M, Furukawa K, Kido M, Matsumoto S, Umesaki Y, et al. (1997) Growth retardation and early death of beta-1,4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells. EMBO J 16: 1850-1857.
33. Malik N, Kallestad JC, Gunderson NL, Austin SD, Neubauer MG, et al. (1989) Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol 9: 2847-2853.
34. Brown TJ, Lioubin MN, Marquardt H (1987) Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol 139: 2977-2983.
35. Ganapathi MK, Weizer AK, Borsellino S, Bukowski RM, Ganapathi R, et al. (1996) Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components. Cell Growth Differ 7: 923-929.
36. Ohata Y, Harada T, Fujii A, Yoshida S, Iwabe T, et al. (2001) Menstrual cycle-specific inhibition of endometrial stromal cell proliferation by oncostatin M. Mol Hum Reprod 7: 665-670.
37. Douglas AM, Goss GA, Sutherland RL, Hilton DJ, Berndt MC, et al. (1997) Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 14: 661-669.
38. Liu J, Hadjokas N, Mosley B, Estrov Z, Spence MJ, et al. (1998) Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine 10: 295-302.
39. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ, et al. (1992) The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255: 1434-1437.
40. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, et al. (1996) Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 271: 32635-32643.
41. Underhill-Day N, Heath JK (2006) Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel. Cancer Res 66: 10891-10901.
42. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
43. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.